A-MANSIA BIOTECH – Trademark Portfolio
Entity Type: 98
A-MANSIA BIOTECH holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 4 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include AKTIGUT and A-MANSIA.
Rue Granbonpré 11
B-1435 Mont-Saint-Guibert
Showing of trademarks Trademarks
Trademark Classifications
A-MANSIA BIOTECH's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does A-MANSIA BIOTECH have?
A-MANSIA BIOTECH has 4 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned, 1 cancelled.
What trademark classes does A-MANSIA BIOTECH file in?
A-MANSIA BIOTECH files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are A-MANSIA BIOTECH's most well-known trademarks?
A-MANSIA BIOTECH's registered trademark portfolio includes well-known marks such as AKTIGUT and A-MANSIA. These are among 2 currently registered trademarks in the portfolio.
What is A-MANSIA BIOTECH's trademark registration success rate?
A-MANSIA BIOTECH has a 50% trademark registration rate, with 2 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.